IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- IDEAYA Biosciences
- Region
- USA
- Scope
- Industry
- Published
- April 6, 2026
- Language
- EN
Topics
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low...
Source route
Continue on ir.ideayabio.com
Leave the platform to read the original full article on the publisher site.
Source: IDEAYA Biosciences
Scope: Industry
Related coverage